AlcoChange is a prescription-only Class IIa SaMD used as an adjunct to standard clinical care. It does not replace standard clinical care.
The treating clinician prescribes AlcoChange for an eligible adult patient (aged 18 or over) with established ARLD. The patient downloads the AlcoChange mobile application and enrols using a unique code provided by their clinical team. The programme runs for 90 days alongside the patient's existing clinical care pathway.
During onboarding, the patient completes a validated AUDIT-C questionnaire to establish a baseline alcohol consumption score. The patient also sets personal goals for reducing or abstaining from alcohol use. This information is used to personalise the behaviour change content delivered throughout the programme.
Each day, the patient logs their alcohol consumption in units. AlcoChange delivers personalised behaviour change notifications drawn from a library of over 150 messages, together with motivational and educational content. The content adapts based on the patient's logged behaviours and engagement patterns, using 34 digital behaviour change techniques grounded in the CyberLiver Behaviour Change (CBC) Model.
The supervising clinical team accesses a web-based clinician dashboard that presents behavioural-risk stratification, patient engagement metrics, and validated questionnaire outputs. Clinical oversight notifications highlight patients whose behavioural patterns indicate increased risk of relapse or disengagement, supporting timely clinical review within the standard care pathway.
At the end of the 90-day programme, a structured review is conducted by the clinical team. The review draws on data collected throughout the programme, including consumption trends, engagement metrics, and questionnaire responses. Where applicable, the patient may continue to be followed up through existing post-market surveillance processes.
AlcoChange delivers behavioural change interventions based on the CBC Model, incorporating 34 digital behaviour change techniques across five domains
Patients set personalised targets for alcohol reduction or abstinence during onboarding. Goals are revisited throughout the programme to reinforce commitment and track progress against self-defined objectives.
Daily alcohol unit logging and structured self-monitoring encourage the patient to maintain awareness of their consumption patterns. Self-management techniques help patients develop routines that support sustained behavioural change.
The application provides structured feedback on logged behaviours, drawing on cognitive behavioural therapy principles. Over 150 behaviour change notifications deliver timely, personalised messages based on the patient's engagement and consumption data.
Targeted content helps patients identify triggers and develop practical coping strategies for high-risk situations. These techniques are designed to support the patient in managing urges and maintaining progress within their daily routine.
The programme reinforces positive behaviours through acknowledgement of progress, milestone recognition, and motivational content. Positive reinforcement techniques encourage continued engagement and help sustain long-term behavioural change.
An optional companion accessory that provides qualitative breath-alcohol detection
The AlcoChange Digital Breathalyser II (ADBII) is an optional Bluetooth-connected accessory designed for indoor use only. It provides a qualitative indication of the presence or absence of alcohol on the breath. The ADBII is non-measuring: it does not quantify blood alcohol concentration or provide a numerical reading.
Breath-test results (alcohol present or absent) are transmitted to the AlcoChange mobile application via Bluetooth and are available to the supervising clinical team through the clinician dashboard. The ADBII supports the overall programme by providing an additional data point for clinical oversight, alongside self-reported alcohol unit logging and questionnaire outputs.
The digital breathalyser is not a mandatory component of the AlcoChange programme. Patients may complete the full 90-day programme using the mobile application alone.
AlcoChange is a prescription-only medical device. Contact us to find out how it can support your hepatology or alcohol care service.
Contact Us